scholarly journals A methyltransferase‐like 14/miR‐99a‐5p/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2‐mediated epigenetic modulation in esophageal squamous cell carcinoma

2021 ◽  
Vol 11 (9) ◽  
Author(s):  
Zhenchuan Liu ◽  
Kaiqing Wu ◽  
Shaorui Gu ◽  
Wenli Wang ◽  
Shiliang Xie ◽  
...  
2020 ◽  
Vol 319 (1) ◽  
pp. C93-C104
Author(s):  
Nuo Li ◽  
Yang Yu ◽  
Baoming Wang

Esophageal squamous cell carcinoma (ESCC) ranks among the five most common cancers in China and has a five-year survival rate of less than 15%. The transcription factor ATPase-family AAA-domain-containing protein 2 (ATAD2) has potential as a therapeutic target in various tumors, and microarray-based gene expression profiling reveals dysregulation of ATAD2 specifically in ESCC. Here we investigated whether ATAD2 could mediate a regulation of cancer stem cell (CSC) biological functions in ESCC. Immunohistochemical staining, reverse transcription quantitative polymerase chain reaction, and Western blot assays all revealed upregulation of ATAD2 in ESCC tissues and cell lines, which furthermore correlated with progression of ESCC. In loss-of-function experiments, silencing of ATAD2 inhibited activation of the Hedgehog signaling pathway, as indicated by reduced expression of glioma-associated oncogene family zinc finger 1 (Gli1), smoothened frizzled class receptor (SMO), and patched 1 (PTCH1). Investigations with 5-ethynyl-2′-deoxyuridine (EdU), Transwell assay, scratch test, flow cytometry, and colony formation assay showed that silencing of ATAD2 or inhibiting the Hedgehog signaling decreased the proliferation, invasion, and migration abilities along with colony formation, but elevated the apoptosis rate of CSCs. Furthermore, in vivo experiments validated the suppressive effect of siRNA-mediated ATAD2 silencing on tumor growth in nude mice. Thus, downregulation of ATAD2 can seemingly restrain the malignant phenotypes of ESCC cells through inhibition of the Hedgehog signaling pathway.


PLoS ONE ◽  
2015 ◽  
Vol 10 (11) ◽  
pp. e0142834 ◽  
Author(s):  
Sheng-Ta Tsai ◽  
Po-Jen Wang ◽  
Nia-Jhen Liou ◽  
Pei-Shan Lin ◽  
Chung-Hsuan Chen ◽  
...  

2020 ◽  
Author(s):  
Wei Cui ◽  
Tingting Fang ◽  
Zhaoheng Duan ◽  
Dongfang Xiang ◽  
Yanxia Wang ◽  
...  

Abstract Background: Platinum-based regimens have been routinely used in the clinical treatment of patients with esophageal squamous cell carcinoma (ESCC). However, administration of these drugs is frequently accompanied by drug resistance. Revealing the underlying mechanisms of the drug resistance and developing agents that enhance the sensitivity to platinum may provide new therapeutic strategies for the patients. Methods: Immunohistochemistry, western blotting, RT-PCR, flow cytometry and immunofluorescence microscopy were used to detect the expression of Shh pathway members and cancer stem cell(CSC) biomarkers in ESCC specimens and cell lines. Functional assays, including MTT, tumorsphere formation assay, RTCA and an in vivo tumour growth assay, were conducted to assess the effect of Dihydroartemisinin (DHA) on the proliferation and renewal ability of ESCC cells. HPLC was used to examine the concention of cisplatin in ESCC cells.Results: We found that the poor outcome of ESCC patients receiving platinum-based regimens was associated with co-expression of Shh and Sox2. The sensitivity of ESCC cell lines to cisplatin was related to their activity of Shh signaling. Manipulating of Shh expression markedly changed the sensitivity of ESCC cells to platinum. Continuous treatment with cisplatin resulted in the activation of Shh signaling and enhanced cancer stem cell-like phenotypes in ESCC cells. DHA, a classic antimalarial drug, was identified as a novel inhibitor of Shh pathway. Treatment with DHA attenuated the cisplatin-induced activation of the Shh pathway in ESCC cells and synergized the inhibitory effect of cisplatin on proliferation, sphere and colony formation of ALDH-positive ESCC cells in vitro and growth of ESCC cell-derived xenograft tumors in vivo. Conclusion: These results demonstrate that the Shh pathway is an important player in cisplatin-resistant ESCC and DHA acts as a promising therapeutic agent to sensitize ESCC to cisplatin treatment.


2013 ◽  
Vol 104 (11) ◽  
pp. 1468-1475 ◽  
Author(s):  
Kazuaki Chikamatsu ◽  
Hiroki Ishii ◽  
Takaaki Murata ◽  
Koichi Sakakura ◽  
Masato Shino ◽  
...  

2017 ◽  
Vol 51 (1) ◽  
pp. 49-62 ◽  
Author(s):  
Hirofumi Kojima ◽  
Tomoyuki Okumura ◽  
Tetsuji Yamaguchi ◽  
Takeshi Miwa ◽  
Yutaka Shimada ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document